IS6915A - Lyfjablanda - Google Patents

Lyfjablanda

Info

Publication number
IS6915A
IS6915A IS6915A IS6915A IS6915A IS 6915 A IS6915 A IS 6915A IS 6915 A IS6915 A IS 6915A IS 6915 A IS6915 A IS 6915A IS 6915 A IS6915 A IS 6915A
Authority
IS
Iceland
Prior art keywords
composition
Prior art date
Application number
IS6915A
Other languages
English (en)
Inventor
Bateman Nicola
Cahill Julie
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0104749A external-priority patent/GB2372444A/en
Priority claimed from SE0102572A external-priority patent/SE0102572D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6915A publication Critical patent/IS6915A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6915A 2001-02-27 2003-08-15 Lyfjablanda IS6915A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0104749A GB2372444A (en) 2001-02-27 2001-02-27 A pharmaceutical formulation comprising bicalutamide and a hydroxypropylmethylcellulose polymer
SE0102572A SE0102572D0 (sv) 2001-07-19 2001-07-19 Pharmaceutical formulation
PCT/GB2002/000766 WO2002067893A2 (en) 2001-02-27 2002-02-22 Pharmaceutical formulation comprising bicalutamide

Publications (1)

Publication Number Publication Date
IS6915A true IS6915A (is) 2003-08-15

Family

ID=26245766

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6915A IS6915A (is) 2001-02-27 2003-08-15 Lyfjablanda

Country Status (22)

Country Link
US (1) US20040067257A1 (is)
EP (1) EP1368001B1 (is)
JP (2) JP3548566B2 (is)
KR (1) KR20030077042A (is)
CN (1) CN1503662A (is)
AR (1) AR032912A1 (is)
AT (1) ATE307571T1 (is)
CA (1) CA2439366A1 (is)
CZ (1) CZ20032225A3 (is)
DE (1) DE60206889T2 (is)
EE (1) EE200300416A (is)
HU (1) HUP0302847A3 (is)
IL (1) IL157389A0 (is)
IS (1) IS6915A (is)
MX (1) MXPA03007641A (is)
NO (1) NO20033785L (is)
NZ (1) NZ527532A (is)
PL (1) PL365746A1 (is)
RU (1) RU2003128971A (is)
SK (1) SK10722003A3 (is)
UY (1) UY27186A1 (is)
WO (1) WO2002067893A2 (is)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
JP4982084B2 (ja) * 2004-02-09 2012-07-25 株式会社サンギ 抗腫瘍剤
KR100539706B1 (ko) * 2005-01-25 2005-12-28 지엘팜텍 주식회사 타크로리무스 및 장용성 고분자를 함유하는 고체분산체
WO2006090129A2 (en) * 2005-02-23 2006-08-31 Astrazeneca Ab Bicalutamide for delivering increasing steady state plasma levels
WO2006109635A1 (ja) 2005-04-06 2006-10-19 Kabushiki Kaisha Sangi 腸管吸収用抗腫瘍剤
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
JPWO2009038112A1 (ja) 2007-09-21 2011-01-06 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
JP5204452B2 (ja) * 2007-10-02 2013-06-05 日医工株式会社 ビカルタミド含有製剤
EP2219624A2 (en) * 2007-11-08 2010-08-25 Glaxo Group Limited Pharmaceutical formulations
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
AU2010332797B2 (en) 2009-12-18 2015-05-28 Catalent Pharma Solutions Gmbh Pharmaceutical oral dosage form containing a synthetic oligosaccharide
CN102525876B (zh) * 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
CN102552103B (zh) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
PL2672967T3 (pl) 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP4450130A3 (en) 2012-09-11 2025-01-08 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
JP2017523206A (ja) * 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
RS66323B1 (sr) 2014-12-05 2025-01-31 Aragon Pharmaceuticals Inc Sastavi protiv raka
MX381829B (es) 2014-12-05 2025-03-13 Aragon Pharmaceuticals Inc Composiciones anticancerígenas.
WO2018108128A1 (zh) * 2016-12-15 2018-06-21 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
JP7654561B2 (ja) 2019-04-11 2025-04-01 アール．ピー． シェーラー テクノロジーズ エルエルシー 浸透性が低いタンパク質、ペプチド、及び小分子の経口送達用の製剤
GB2584341B (en) * 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US12576063B2 (en) 2020-03-20 2026-03-17 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
EP0748220A4 (en) * 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
WO2002080902A1 (en) * 2001-04-02 2002-10-17 Astrazeneca Ab Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product

Also Published As

Publication number Publication date
JP3548566B2 (ja) 2004-07-28
DE60206889D1 (de) 2005-12-01
JP2004143185A (ja) 2004-05-20
NO20033785L (no) 2003-10-24
PL365746A1 (en) 2005-01-10
RU2003128971A (ru) 2005-03-10
CN1503662A (zh) 2004-06-09
HUP0302847A3 (en) 2005-05-30
AR032912A1 (es) 2003-12-03
MXPA03007641A (es) 2003-12-04
CA2439366A1 (en) 2002-09-06
KR20030077042A (ko) 2003-09-29
CZ20032225A3 (cs) 2003-11-12
NZ527532A (en) 2004-12-24
IL157389A0 (en) 2004-05-12
SK10722003A3 (sk) 2004-02-03
HUP0302847A2 (hu) 2003-12-29
WO2002067893A3 (en) 2003-01-16
UY27186A1 (es) 2002-09-30
NO20033785D0 (no) 2003-08-26
DE60206889T2 (de) 2006-07-27
JP2004521918A (ja) 2004-07-22
US20040067257A1 (en) 2004-04-08
EP1368001B1 (en) 2005-10-26
ATE307571T1 (de) 2005-11-15
EE200300416A (et) 2003-12-15
WO2002067893A2 (en) 2002-09-06
EP1368001A2 (en) 2003-12-10

Similar Documents

Publication Publication Date Title
IS6915A (is) Lyfjablanda
FI20010780A0 (fi) Parannetut koostumukset
DK1671949T3 (da) Substituerede pyridinylaminer
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
BR0210619A (pt) composição
IS7081A (is) Lyfjablanda
DE50206892D1 (de) Substituierte imidazotriazinone
ATE335486T1 (de) Hydrazono-malonitrile
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
DE50203412D1 (de) Schwenkkolbenverdränger
DE60214433D1 (de) Zughakensystem
DE50203984D1 (de) Kugelgelenk
ATE355059T1 (de) Isoxazolopyridinone
DK1406858T3 (da) Substituerede 4-aminocyklohexanoler
DE50201862D1 (de) Messwandler
DE50203093D1 (de) Losradlager
ATA18372001A (de) Gelenksbolzenbaueinheit
ATE319694T1 (de) Phenylalkyne
ITTO20020744A0 (it) Composizione
DE50202088D1 (de) Garmodulsystem
ATA13992002A (de) Schlackengranulierungsanlage
ITTO20020745A0 (it) Composizione
DE50108381D1 (de) Synchronisierschaltungsanordnung
DE10295006D2 (de) Bauwerksabdichtung
DE60200786D1 (de) Feste zusammensetzung